Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Quote. Real-time Euronext Paris - 09/27 11:35:01 am
3.482 EUR   -4.24%
11:10aGLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
04:52aNOVACYT : Interim Accounts June 2021
PU
04:52aNOVACYT : Rapport D'Activitie Semestriel 2021
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
3.714(c) 3.706(c) 3.604(c) 3.636(c) 3.482(c) Last
747 316 218 932 222 832 271 686 609 033 Volume
+7.00% -0.22% -2.75% +0.89% -4.24% Change
More quotes
Estimated financial data (e)
Sales 2021 112 M 131 M 131 M
Net income 2021 70,0 M 81,9 M 81,9 M
Net cash position 2021 90,4 M 106 M 106 M
P/E ratio 2021 4,00x
Yield 2021 -
Sales 2022 86,6 M 101 M 101 M
Net income 2022 18,0 M 21,1 M 21,1 M
Net cash position 2022 190 M 222 M 222 M
P/E ratio 2022 15,8x
Yield 2022 -
Capitalization 246 M 288 M 288 M
EV / Sales 2021 1,39x
EV / Sales 2022 0,64x
Nbr of Employees 174
Free-Float 99,0%
More Financials
Company
Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of... 
Sector
Biotechnology & Medical Research
Calendar
09/29 | 08:00amShareholder meeting
More about the company
Ratings of Novacyt
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NOVACYT
11:10aGLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
04:52aNOVACYT : Interim Accounts June 2021
PU
04:52aNOVACYT : Rapport D'Activitie Semestriel 2021
PU
03:03aFTSE 100 Seen Opening Higher
DJ
02:12aNOVACYT : Half year 2021 results
PU
02:05aNOVACYT : Earnings Flash (NCYT.L) NOVACYT Posts H1 Loss GBP-0.18
MT
02:05aNOVACYT : Earnings Flash (NCYT.L) NOVACYT S.A. Reports H1 Revenue GBP54M
MT
09/16FTSE 100 Rises on Speculation over UK's Travel Restrictions Removal
DJ
09/16GLOBAL MARKETS LIVE : Thales, Nestlé, Evergrande, AMC, Walmart...
09/16FTSE Rises, THG Shares Fall After 1st Half Loss as Shake-Up Looms
DJ
09/16NOVACYT : Dispute With UK Health Department Threatens To Wipe Out H1 Profit
MT
09/16FTSE Rises, Ashtead Gains After 1Q Profit Boost, Guidance Increase
DJ
09/16Novacyt Says Covid-19 Contract Dispute with UK Health Department Continues
DJ
09/16Novacyt to Revise Down 1st Half Revenue Due to UK Covid-19 Contract Dispute -- Update
DJ
09/16NOVACYT : Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results
PU
More news
News in other languages on NOVACYT
10:56aNOVACYT : dans le rouge à cause du litige au Royaume-Uni
04:52aNOVACYT : Comptes intérimaires juin 2021
04:52aNOVACYT : Rapport d'Activité Semestriel 2021
03:34aNOVACYT : perte nette essuyée au 1er semestre
03:09aLes valeurs à suivre aujourd'hui à la Bourse de Paris Lundi 27 septembre 2021
More news
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | ALNOV | FR0010397232 | MarketScreener
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 1
Last Close Price 3,48 €
Average target price 4,10 €
Spread / Average Target 17,7%
EPS Revisions
Managers and Directors
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Reginald A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-62.90%301
MODERNA, INC.311.74%173 624
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
REGENERON PHARMACEUTICALS32.25%66 425
WUXI APPTEC CO., LTD.35.04%59 817